Tilray Boosts Cannabis Production 31% to 275 Metric Tonnes for Global Demand

Tilray Brands is significantly expanding cannabis production in Canada and Europe, the latest sign that some of the industry’s largest operators are preparing for a cannabis market increasingly defined by scale, international distribution and access to regulated medical markets.

The company said Thursday that it has increased annual cultivation capacity from approximately 210 metric tonnes to 275 metric tonnes, a roughly 31% increase, following expanded production at facilities in Quebec and Portugal.

The additional capacity is intended largely to support growing international medical cannabis demand, with Tilray already moving Canadian-grown cannabis into its supply infrastructure in Europe and Australia.

The expansion comes at an important moment for the cannabis industry. Curaleaf’s pursuit of Aurora Cannabis has put international scale at the center of the M&A conversation, while Organigram, Village Farms and other major operators have been expanding their production or international footprints. In the U.S., Glass House Brands has pursued a different version of the same scale strategy through large-format cultivation, with international markets representing another potential avenue for operators as the global industry develops.

Tilray’s announcement adds another major producer to that broader race.

From 210 to 275 Metric Tonnes

Tilray said the expansion increases its worldwide annual cultivation capacity by approximately 65 metric tonnes.

Its Quebec facility accounts for 30 metric tonnes of additional annual capacity, with the added production serving the domestic Quebec market as well as international destinations.

More importantly for Tilray’s global strategy, cannabis grown in Quebec is now being shipped in bulk directly to company facilities in Portugal and Australia.

Tilray also expects the Quebec facility to achieve EU-GMP certification within the next 12 months. That certification would give the company another production source capable of meeting the standards required across key regulated medical cannabis markets.

Portugal remains the anchor of Tilray’s European production network. The company said it has increased output at its EU-GMP-certified Portuguese facility to strengthen supply into Germany, the United Kingdom and other European markets.

Germany is another piece of the strategy. Tilray said its Aphria RX cultivation facility there is fully utilized, while the company has launched its new ARX medical cannabis brand.

“Tilray is defining what global leadership in cannabis looks like,” CEO Irwin D. Simon said in announcing the expansion. “We are expanding production across Canada and Europe, increasing global capacity to approximately 275 metric tonnes, and strengthening the supply infrastructure needed to serve patients and partners across the world’s most important medical cannabis markets.”

Cannabis Companies Are Thinking Bigger

The significance of the announcement extends beyond another 65 metric tonnes of cannabis.

A growing group of public cannabis companies is making increasingly large bets on production scale, distribution and international markets.

Curaleaf’s (OTC: CURLF) proposed takeover of Aurora is perhaps the clearest recent example. Curaleaf Executive Chairman Boris Jordan has argued that Aurora’s Canadian indoor cultivation and established international operations could complement Curaleaf’s existing European platform, creating substantially greater scale outside the United States.

Organigram (NASDAQ: OGI; TSX: OGI) is pursuing international scale with heavyweight financial backing. Its acquisition of Germany’s Sanity Group established a larger European platform, supported by C$65.2 million in new equity financing from strategic investor British American Tobacco (NYSE: BTI; LSE: BATS), one of the world’s largest tobacco companies.

Glass House Brands (Cboe CA: GLAS.A.U; OTCQX: GLASF) represents a somewhat different model, with massive greenhouse cultivation capacity in California and the economics of producing cannabis at industrial scale; if marijuana moves to Schedule III, federally authorized exports could potentially flow through DEA-registered facilities and compliant international supply chains, opening a pathway to overseas medical markets.

Meanwhile, Village Farms International (NASDAQ: VFF) is proving the scale model can work internationally. Its Pure Sunfarms operation combines high-yield, low-cost greenhouse production with a growing export business, including $20.9 million in international cannabis sales last quarter, up 74% year over year, supported by demand from markets including Germany.

Taken together, these companies illustrate a larger shift: some of cannabis’ biggest operators are positioning themselves for a market that could eventually extend well beyond individual U.S. states or Canada’s domestic recreational market.

The strategies aren’t identical, and scale alone does not guarantee profitability. But the direction of travel is becoming difficult to ignore.

Why International Markets Matter

International medical cannabis markets can offer producers something increasingly difficult to find in mature North American markets: new sources of demand.

Canada has struggled with oversupply and price compression, while U.S. operators remain constrained by a state-by-state market structure and federal prohibition. Regulated medical markets in Europe and elsewhere create another potential destination for cannabis produced by companies capable of meeting pharmaceutical-grade standards and navigating complex import requirements.

Tilray already has infrastructure designed around that model.

The company says its medical cannabis products reach patients, physicians, pharmacies, hospitals, researchers and governments across 20 countries. Its platform combines cultivation with pharmaceutical distribution and patient-access businesses, including HelloMD in Canada and Lyphe Clinic in the United Kingdom.

That infrastructure becomes more valuable if medical cannabis demand continues expanding across Germany, the U.K., Australia and other regulated markets.

It also helps explain why EU-GMP-certified production has become strategically important. Growing cannabis at scale is only part of the equation. Companies need compliant production, import and export capabilities, distribution infrastructure and access to patients once the product reaches its destination.

Tilray is now increasing the amount of cannabis it can move through that system.

A Race for the Next Cannabis Market

The industry spent years building cultivation capacity ahead of demand, particularly in Canada, with painful consequences for investors when supply overwhelmed the market.

That history makes today’s expansion strategies worth watching carefully.

The difference this time is that companies such as Tilray are increasingly building production around multiple regulated markets rather than a single domestic opportunity.

Tilray’s Quebec cannabis can move toward Europe and Australia. Portugal can supply European medical markets. Germany provides domestic cultivation and patient access. Its U.K. operations add another route into one of Europe’s developing medical cannabis markets.

Whether international demand ultimately absorbs the capacity being built remains the critical question.

But Tilray’s move to roughly 275 metric tonnes of annual cultivation capacity makes one thing clearer: as Curaleaf, Aurora, Organigram, Village Farms, Glass House and others pursue their own versions of scale, the next stage of cannabis competition may increasingly be fought across borders rather than within them.